Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma-Reference-Cited by-同舟云学术

Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma

Published:2013-01-18 Issue:8 Volume:119 Page:1547-1554
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Kroeger Nils,Klatte Tobias,Chamie Karim,Rao P. Nagesh,Birkhäuser Frédéric D.,Sonn Geoffrey A.,Riss Joseph,Kabbinavar Fairooz F.,Belldegrun Arie S.,Pantuck Allan J.

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.27947/fullpdf

Reference27 articles.

1. Prognostic factors and predictive models in renal cell carcinoma: a contemporary review;Sun;Eur Urol.,2011

2. Genetic and functional studies implicate HIF1alpha as a 14q kidney cancer suppressor gene;Shen;Cancer Discov.,2011

3. Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma;Patard;Int J Cancer.,2008

4. Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma;Klatte;J Clin Oncol.,2009

5. Von Hippel-Lindau disease;Kaelin;Annu Rev Pathol.,2007

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. RIGATonI: An R software for Rapid Identification of Genomic Alterations in Tumors affecting lymphocyte Infiltration;2024-03-04

2. Successful long-term management of metastatic clear cell renal cell carcinoma with nivolumab: a case report and literature review;ecancermedicalscience;2023-11-30

3. Contemporary Clinical Definitions, Differential Diagnosis, and Novel Predictive Tools for Renal Cell Carcinoma;Biomedicines;2022-11-14

4. Pathological and genetic markers improve recurrence prognostication with the University of California Los Angeles Integrated Staging System for patients with clear cell renal cell carcinoma;European Journal of Cancer;2022-06

5. Emerging glioneuronal and neuronal tumors: case-based review;Brain Tumor Pathology;2022-01-20